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doi:10.1016/j.joca.2010.02.011The Osteoarthritis Research Society International (OARSI) is
committed to developing consensus-driven OA treatment guide-
lines predicated on a continually updated database of the research
evidence. This commitment extends beyond production of the ﬁrst
set of guidelines and endeavors to keep the database current by
incorporating new research evidence into periodic updates of the
consensus statements. This process can be viewed a cycle of activ-
ities that break down into (1) evidence synthesis (2) a consensus
process and (3) surveillance of the database for changes in evidence
that should initiate revision of the consensus statement. While
methodologies are established for ﬁrst two undertakings, the
initiative to test an updated dataset for pivotal changes is novel.
Inherent to this process are a number of methodological and logis-
tical challenges that include the approach to layering new data on
top of the old and the formulation of decision rules to deﬁne pivotal
change. For these reasons, and especially because of intrigue about
what lines of evidence might have changed, I was greatly interested
to review the OARSI Treatment Guidelines Committee's recent
report of their surveillance of the updated data1.
Just to digress for a moment, I would point out that the ﬁrst two
reports from the OATreatment Guidelines Committee rank ﬁrst and
second in the ranks for the number of downloads from the Osteo-
arthritis and Cartilage during 20092,3, indicating an intense level of
interest. This is notable because OA treatment guidelines have also
recently been developed by a number of other groups including the
National Institute of Clinical Excellence (NICE), the European
League Against Rheumatism (EULAR), the Orthopedic Research
Society (ORS) and the American College of Rheumatology
(ACR)4e8. We might infer from these two sets of observations that
the motivation for different groups to produce their own version
of OA guidelines will continue, perhaps to allow for application of
contrasting methodologies and to serve differing constituencies.
Nevertheless, inherent in all this parallel activity must be some
duplication of effort, especially in relation to derivation of the
primary database. In this respect, the OARSI endeavor could serve
the broader community through sharing their current evidence
repository. Of course, this will be contingent on many factors nots Research Society International. Pleast an acceptance of its methodological rigor and data quality,
and a willingness to share.
So how do Zhang et al. overcome the methodological challenges
of identifying important changes in research evidence between
2006 and 2009? This is a task of almost insurmountable magnitude
that requires summarizing current evidence from heterogeneous
evidence sources across the spectrum of OA treatments. Zhang et
al. accomplish this by sifting and ranking research reports, using
the highest level evidence, and, where possible, performing their
own pooled analyses of trial results. Where a typical meta-analysis
would devote an entire manuscript to assessment of a single inter-
vention, this report considers many treatments in one document.
The trade-off of this approach is a loss of transparency and detail.
On the other hand, it is important to appreciate that their task
was not to revise the recommendations but to determine whether
changes have occurred that should prompt such revisions. As the
authors point out, this is not a restatement of the guidelines and
should not be interpreted as such. One lingering concern, however,
is the lack of any process or algorithm to identify signiﬁcant
changes in the dataset.
So what has changed in the evidence base? There are now
positive results for exercise (hip OA), aquatic therapy, rosehip
supplements and avocado soybean unsaponiﬁables. New meta-
analyses of weight reduction now show statistical signiﬁcance
around modest beneﬁts for pain and physical function in knee
OA. On the other hand, electromagnetic ﬁeld therapy, which had
positive results in 2006 is now viewed as ineffective based on anal-
ysis of pooled trial data; and trials of glucosamine hydrochloride (as
opposed to sulfate) have also been conclusively negative.
Zhang et al. exert a higher level of scrutiny on subtle changes in
the pooled evidencewhen these might impact consensus. Themost
prominent of these relates to acetaminophen, formerly a core
recommendation for OA, for which they now infer little or no efﬁ-
cacy, and which has been impugned in two observational studies
for associations with gastrointestinal and renal adverse effects
(even thought these are highly confounded by indication).
However, when we independently examined the data sources ofublished by Elsevier Ltd. All rights reserved.
Fig. 1. Graph depicting time-dependent trajectory of the therapeutic effect of IAHA when compared with intra-articular corticosteroids. Note: Adapted from “Relative efﬁcacy of
hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: Meta-analysis” by RR Bannuru, NS Natov, IE Obadan, CH Schmid, TE McAlindon, 2009, Osteoarthritis
& Cartilage, 17(supplement), p. S269. Copyright 2009 OARSI by Elsevier Ltd. Adapted with permission.
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change was, at least in part, attributable to a change in the statis-
tical methodology used between the ﬁrst and second meta-anal-
ysis. This does not necessarily invalidate the suggestion that there
has been a change in the evidence, but it does highlight how the
trade-off between scale and granularity could lead to erroneous
interpretations.
Another situation that illustrates this semantic difference
between detecting a difference in interpretation vs an actual change
in the research evidence is the analysis of intra-articular hyaluronic
acid (IAHA). It turns out that IAHA, based on two careful recent
meta-analyses, has a time-dependent trajectory of therapeutic
effect (Fig. 1)11,12. Thus, the time point at which its outcome is
assessed will inﬂuence its apparent effectiveness. This may explain
the apparent differences between 2006 and 2009 because the
meta-analysis which provided the 2006 estimate of efﬁcacy was
measured 2e3 months post-intervention13, whereas the 2009
values originate from a 1e4 week time point.
Therefore, itmaybemoreappropriate toviewvaryingeffect sizes
from separate analyses as differences in interpretation rather than
a change inmeasured efﬁcacy. These differences are still important,
though, as signals that the evidence may need to be re-evaluated.
Ultimately, if wewish to track changes in the apparent effective-
ness of an intervention over time, we will need a frequently (or
continually) updated repository of high-quality data in a formula-
tion that permits serial effect size computations and pooled anal-
ysis using a variety of approaches. These characteristics would
make this database a valuable resource that could beneﬁt other
organizations and investigators. Synergy among groups will help
develop more encompassing techniques, such as network meta-
analysis, that would allow us to compare data from multiple inter-
vention types and rank their relative efﬁcacy. The ﬁeld of evidence
synthesis is exciting and developing, and one to which OARSI is
making commendable contributions.Author contributions
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